Abstract
Despite radical surgery and multi-agent chemotherapy, less than one third of patients with recurrent or metastatic osteosarcoma (OS) survive. The limited efficacy of current therapeutic approaches to target tumor-initiating cells (TICs) may explain this dismal outcome. The purpose of this study was to assess the impact of modified T cells expressing a human epidermal growth factor receptor (HER2)-specific chimeric antigen receptor in the OS TIC compartment of human established cell lines. Using the sarcosphere formation assay, we found that OS TICs were resistant to increasing methotrexate concentrations. In contrast, HER2-specific T cells decreased markedly sarcosphere formation capacity and the ability to generate bone tumors in immunodeficient mice after orthotopic transplantation. In vivo, administration of HER2-specific T cells significantly reduced TICs in bulky tumors as judged by decreased sarcosphere forming efficiency in OS cells isolated from explanted tumors. We demonstrate that HER2-specific T cells target drug resistant TICs in established OS cell lines, suggesting that incorporating immunotherapy into current treatment strategies for OS has the potential to improve outcomes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
Purchase on Springer Link
Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Marina N, Gebhardt M, Teot L, Gorlick R . Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9: 422–441.
Siclari VA, Qin L . Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 2010; 5: 78.
Rosen JM, Jordan CT . The increasing complexity of the cancer stem cell paradigm. Science 2009; 324: 1670–1673.
Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 2010; 70: 4602–4612.
Tirino V, Desiderio V, d′Aquino R, De Francesco F, Pirozzi G, Graziano A et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 2008; 3: e3469.
Murase M, Kano M, Tsukahara T, Takahashi A, Torigoe T, Kawaguchi S et al. Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer 2009; 101: 1425–1432.
Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005; 7: 967–976.
Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K, Takakura Y . Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol 2009; 34: 1381–1386.
Lou N, Wang Y, Sun D, Zhao J, Gao Z . Isolation of stem-like cells from human MG-63 osteosarcoma cells using limiting dilution in combination with vincristine selection. Indian J Biochem Biophys 2010; 47: 340–347.
Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999; 17: 2781–2788.
Morris CD, Gorlick R, Huvos G, Heller G, Meyers PA, Healey JH . Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res 2001; 382: 59–65.
Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 2009; 17: 1779–1787.
Rainusso N, Man TK, Lau CC, Hicks J, Shen JJ, Yu A et al. Identification and gene expression profiling of tumor-initiating cells isolated from human osteosarcoma cell lines in an orthotopic mouse model. Cancer Biol Ther 2011; 12: 278–287.
Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008; 68: 4674–4682.
Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003; 101: 1905–1912.
Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006; 108: 3890–3897.
Jaffe N, Gorlick R . High-dose methotrexate in osteosarcoma: let the questions surcease-time for final acceptance. J Clin Oncol 2008; 26: 4365–4366.
Wen YH, Koeppen H, Garcia R, Chiriboga L, Tarlow BD, Peters BA et al. Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Hum Pathol 2007; 38: 1184–1191.
Visvader JE, Lindeman GJ . Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755–768.
Atkinson RL, Zhang M, Diagaradjane P, Peddibhotla S, Contreras A, Hilsenbeck SG et al. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med 2010; 2: 55ra79.
Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672–679.
Boman BM, Wicha MS . Cancer stem cells: a step toward the cure. J Clin Oncol 2008; 26: 2795–2799.
West GW, Weichselbaum R, Little JB . Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 1980; 40: 3665–3668.
Acknowledgements
This research was supported by The Children's Cancer Research Fund (NR and NA), the St Baldrick's Foundation (NR) and the Alex's Lemonade Stand Pediatric Cancer Foundation (NA) and the CPRIT Grant RP101335.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on Cancer Gene Therapy website
Supplementary information
Rights and permissions
About this article
Cite this article
Rainusso, N., Brawley, V., Ghazi, A. et al. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther 19, 212–217 (2012). https://doi.org/10.1038/cgt.2011.83
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/cgt.2011.83
Keywords
This article is cited by
-
B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo
BMC Cancer (2022)
-
Advanced development of ErbB family-targeted therapies in osteosarcoma treatment
Investigational New Drugs (2019)
-
Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
Protein & Cell (2018)
-
Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics
Archives of Pharmacal Research (2016)
-
Bone microenvironment signals in osteosarcoma development
Cellular and Molecular Life Sciences (2015)